PURPOSE: Lung cancer is the third most common type of cancer in Europe and is the first cause of death by cancer worldwide. Non-small cell lung cancer accounts for 75-85% of all histological types of LC. The transforming growth factor beta 1 is a multifunctional regulatory polypeptide that controls many aspects of cellular function (cellular proliferation, differentiation, migration, apoptosis, immune surveillance). TGFB1+869T>C is a functional polymorphism described in TGFB1 gene and this transition has been associated with higher circulating levels of TGFß1 that may modulate cellular microenvironment and consequently LC development and prognosis. METHODS: We studied TGFB + 869T > C functional polymorphism by allelic discrimination using 7300 real-time polymerase chain reaction system in 305 patients with NSCLC and 380 healthy individuals. RESULTS: We found an increased risk for C carriers to develop NSCLC, both epidermoid NSCLC and non-epidermoid NSCLC (odds ratio (OR) = 2.03, P < 0.0001, OR = 2.37, P < 0.001 and OR = 1.83, P = 0.001, respectively). TGFB1+869T>C functional polymorphism may influence NSCLC susceptibility with impact in cellular microenvironment. CONCLUSIONS: Our results suggest that individual differences influence the susceptibility to LC and tumoral behavior. This genetic profiling may help define higher risk groups for an individualized chemoprevention strategy and therapy.
PURPOSE: Lung cancer is the third most common type of cancer in Europe and is the first cause of death by cancer worldwide. Non-small cell lung cancer accounts for 75-85% of all histological types of LC. The transforming growth factor beta 1 is a multifunctional regulatory polypeptide that controls many aspects of cellular function (cellular proliferation, differentiation, migration, apoptosis, immune surveillance). TGFB1+869T>C is a functional polymorphism described in TGFB1 gene and this transition has been associated with higher circulating levels of TGFß1 that may modulate cellular microenvironment and consequently LC development and prognosis. METHODS: We studied TGFB + 869T > C functional polymorphism by allelic discrimination using 7300 real-time polymerase chain reaction system in 305 patients with NSCLC and 380 healthy individuals. RESULTS: We found an increased risk for C carriers to develop NSCLC, both epidermoid NSCLC and non-epidermoid NSCLC (odds ratio (OR) = 2.03, P < 0.0001, OR = 2.37, P < 0.001 and OR = 1.83, P = 0.001, respectively). TGFB1+869T>C functional polymorphism may influence NSCLC susceptibility with impact in cellular microenvironment. CONCLUSIONS: Our results suggest that individual differences influence the susceptibility to LC and tumoral behavior. This genetic profiling may help define higher risk groups for an individualized chemoprevention strategy and therapy.
Authors: Kyong Hwa Park; Sle Gi Lo Han; Young Mi Whang; Hyo Jung Lee; Young Do Yoo; Jae Won Lee; Sang Won Shin; Yeul Hong Kim Journal: Cancer Genet Cytogenet Date: 2006-08
Authors: K Uchida; M Nagatake; H Osada; Y Yatabe; M Kondo; T Mitsudomi; A Masuda; T Takahashi; T Takahashi Journal: Cancer Res Date: 1996-12-15 Impact factor: 12.701
Authors: D J Grainger; K Heathcote; M Chiano; H Snieder; P R Kemp; J C Metcalfe; N D Carter; T D Spector Journal: Hum Mol Genet Date: 1999-01 Impact factor: 6.150
Authors: Loïc Le Marchand; Christopher A Haiman; David van den Berg; Lynne R Wilkens; Laurence N Kolonel; Brian E Henderson Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-03 Impact factor: 4.254
Authors: A L Teixeira; R Ribeiro; A Morais; F Lobo; A Fraga; F Pina; F M Calais-da-Silva; F E Calais-da-Silva; R Medeiros Journal: Pharmacogenomics J Date: 2009-06-02 Impact factor: 3.550
Authors: Jie Lin; Charles Lu; David J Stewart; Jian Gu; Maosheng Huang; David W Chang; Scott M Lippman; Xifeng Wu Journal: Carcinogenesis Date: 2012-06-04 Impact factor: 4.944
Authors: Anand Pathak; Angela S Wenzlaff; Paula L Hyland; Michele L Cote; Greg R Keele; Susan Land; Matthew L Boulton; Ann G Schwartz Journal: J Cancer Ther Res Date: 2014
Authors: Paula Fernanda Vázquez; María José Carlini; María Cecilia Daroqui; Lucas Colombo; Mercedes Liliana Dalurzo; David Eduardo Smith; Julieta Grasselli; María Guadalupe Pallotta; Marcelo Ehrlich; Elisa Dora Bal de Kier Joffé; Lydia Puricelli Journal: Clin Exp Metastasis Date: 2013-07-06 Impact factor: 5.150